RS Research presents first-in-human phase 1 results of RS-0139 at ESMO Congress 2026

29 October 2026


RS Research, a clinical-stage biotechnology company developing smart nanomedicines for targeted oncology therapies, presented detailed results from the completed Phase 1a/1b clinical trial of its lead investigational candidate, RS-0139, at ESMO Congress 2026, held in Madrid, Spain, on 23-27 October.

RS-0139 was developed using Sagitta® Bir, part of RS Research’s proprietary Sagitta® targeted drug delivery platform family. The investigational medicine combines docetaxel with a polymer-based carrier and an integrin-targeting peptide, designed to modify drug delivery and systemic exposure while addressing the longstanding efficacy-toxicity trade-off of conventional chemotherapy.

The first-in-human, multicenter, open-label study evaluated safety, tolerability, pharmacokinetics and exploratory antitumor activity in patients with advanced solid tumors. Following single-dose accelerated titration, which established a maximum tolerated dose of 75 mg/m², the study investigated repeated administration every three weeks at 40 and 60 mg/m².

At the repeat-dose levels of 40-60 mg/m², no neutropenia was observed and no patient required G-CSF support. Pharmacokinetic analyses showed a low released-docetaxel fraction, approximately 4% of total, with no accumulation across cycles. Peripheral neuropathy was the principal safety finding with repeated dosing and will be a key consideration for further development. Exploratory analyses also identified substantial reductions in the tumor-associated marker CA-125 in two patients with gynecological cancers. These early findings provide a foundation for further investigation but do not establish clinical efficacy or comparative safety.

The presentation represents an important step in the clinical translation of Sagitta® as RS Research prepares for international Phase 2 development.

ePoster Title: First-in-human phase Ia/Ib study of RS-0139, an integrin-targeted docetaxel prodrug, in advanced solid tumors

ePoster Number: 1095eP

Date: 23-27 October 2026

Location: IFEMA Madrid, Spain

Clinical Trial: NCT04261413

More information available at publication page

 

About RS Research

RS Research is a clinical-stage biotechnology company developing smart nanomedicines for targeted therapies through its proprietary Sagitta® drug delivery platform family. With its lead investigational candidate RS-0139 having completed Phase 1, the company is advancing an oncology pipeline supported by integrated drug development expertise, GMP-certified manufacturing capabilities and European Medicines Agency SME status.

For media inquiries: pr@rsresearch.net

For scientific inquiries: medicalinformation@rsresearch.net

www.rsresearch.net

Archive notice: information reflects the date of publication. See current company overview.
Share this entry
RS Research develops investigational programs. Content on this website is for general informational purposes only, does not provide medical advice and relates to products that are not approved for general use. Archive notice: information reflects the date of publication. Full disclaimer and important information ↗